Skip to main content

Table 1 Baseline characteristics of patients

From: Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

Characteristics

Active (n = 33)

Placebo (n = 31)

P-value

Age, median

37.2 (23–57)

36.4 (22–52)

0.06

Women, No. (%)

22 (66.6)

21 (67.7)

0.82

Employment status, No. (%)

 Employed or student

21 (63.6)

24 (77.4)

 

 Household

9 (27.2)

3 (9.6)

0.051

 Unemployed

3 (9)

4 (12.9)

 

Body mass index, median (IQR)

18.47 (19.2–30.4)

20.67 (20.07–27.85)

0.06

Smoking status, No. (%)

 Never

20 (60)

17 (54)

 

 Former

5 (15)

6 (19)

0.36

 Current

8 (24)

8 (25)

 

Comorbidities, No. (%)

 Seasonal allergies

8 (24)

5 (16)

0.83

 Depression

4 (12)

2 (6)

 Anxiety

5 (15)

4 (13)

 Asthma

2 (6)

3 (9)

 Emotional stress

5 (15)

6 (19)

 Sleep problems

7 (21)

8 (25)

Duration of migraine, No. (%)

 ≤ 2 years

19 (57.6)

17 (54.8)

0.216

 > 2 years

14 (42.4)

14 (45.2)

Number of Attacks (mean ± SD)

4.67 ± 1.05

4.61 ± 1.09

0.743

Pre-treatment Median (IQR)

5 (2)

5 (1)

Pain Severity (mean ± SD)

7.85 ± 1.03

7.90 ± 0.91

0.899

Pre-treatment Median (IQR)

8 (2)

8 (2)

  1. BMI Body–mass index, SD Standard deviation, IQR Interquartile range